Lundbeck presents positive results from migraine drug trial

New data from a study of Lundbeck's migraine drug Vyepti shows a significant effect on patients who have been through two to four prior failed treatments with other types of migraine drugs.

Photo: Jens Dresling

Both primary and secondary endpoints were met in Lundbeck's phase IIIb trial, which goes under the name Deliver, of the migraine drug Vyepti, it reports in a press release on Monday morning.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs